Patents by Inventor Daren Stephens

Daren Stephens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Phospholipase A2 inhibitors and their use in treating neurological injury and disease
    Patent number: 8420852
    Abstract: Phospholipase A2 (PLA2) forms are expressed in spinal cord whose inhibition induces a potent antihyperalgesia. PLA2 inhibitor compounds are provided that include a common motif consisting of a 2-oxoamide with a hydrocarbon tail and a four carbon tether. The compounds block Group IVA calcium dependent PLA2 (cPLA2) and/or Group VIA calcium independent PLA2 (iPLA2) and/or Group V secreted PLA2 (sPLA2). Pharmaceutical compositions of compounds having cPLA2 inhibitory activity (but not iPLA2 or sPLA2 inhibitory activity) are useful in treating multiple sclerosis, while compositions of compounds having sPLA2 inhibitory activity (as well as iPLA2 and CPLA2 activity) are useful in treating spinal cord injuries (with related functional recovery).
    Type: Grant
    Filed: July 3, 2008
    Date of Patent: April 16, 2013
    Assignee: The Regents of the University of California
    Inventors: Edward A. Dennis, Daren Stephens, Samuel David, Ruben Lopez-Vales, Athena Kalyvas, George Kokotos, Violetta Constantinou-Kokotou, Efrosini Barbayianni, Victoria Magrioti
  • Phospholipase A2 Inhibitors and their Use in Treating Neurological Injury and Disease
    Publication number: 20110105610
    Abstract: Phospholipase A2 (PLA2) forms are expressed in spinal cord whose inhibition induces a potent antihyperalgesia. PLA2 inhibitor compounds are provided that include a common motif consisting of a 2-oxoamide with a hydrocarbon tail and a four carbon tether. The compounds block Group IVA calcium dependent PLA2 (cPLA2) and/or Group VIA calcium independent PLA2 (iPLA2) and/or Group V secreted PLA2 (sPLA2). Pharmaceutical compositions of compounds having cPLA2 inhibitory activity (but not iPLA2 or sPLA2 inhibitory activity) are useful in treating multiple sclerosis, while compositions of compounds having sPLA2 inhibitory activity (as well as iPLA2 and CPLA2 activity) are useful in treating spinal cord injuries (with related functional recovery).
    Type: Application
    Filed: July 3, 2008
    Publication date: May 5, 2011
    Inventors: Edward A. Dennis, Daren Stephen, Samuel David, Ruben Lopez-Vales, Athena Kalyvas, George Kokotos, Violetta Constantinou-Kokoton, Efrosini Barbayianni, Victoria Magrioti
  • PERFLUOROKETONE COMPOUNDS AND USES THEREOF
    Publication number: 20100048727
    Abstract: Novel perfluoroketone compounds of formula [I] and [Ia] are described. Also described are uses thereof, such as for inhibition of phospholipase A2 activity. Therapeutic uses thereof are also described, such as for the treatment of neural conditions and/or inflammatory conditions, such as demyelinating (e.g., multiple sclerosis) and neural injury (e.g., spinal cord injury).
    Type: Application
    Filed: April 4, 2008
    Publication date: February 25, 2010
    Inventors: Samuel David, Athena Kalyvas, Ruben Lopez-Vales, George Kokotos, Violetta Constantinou-Kokotou, Constantinos Baskakis, Christoforos G. Kokotos, Edward A. Dennis, Daren Stephens
  • Bioreactor vessel
    Patent number: D785195
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: April 25, 2017
    Assignee: TAP Biosystems (PHC) Limited
    Inventors: Stephen Owen, Daren Stephen Huttlestone